Back to OGNView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/24/2005
Fosavance
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Fosavance reduces the risk of vertebral and hip fractures.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
MK0954, /Duration of Treatment : 5 YearsPhase 3
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
MK0906, finasteride / Duration of Treatment: 48 weeksPhase 3
Benign Prostatic Hyperplasia
SCH 900962 / Corifollitropin alfa / Org 36286Phase 3
Infertility
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeksPhase 3
Osteoporosis
ibandronatePhase 3
Postmenopausal Osteoporosis
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts